Background
The clinical utility of pretest probability models in the diagnosis of VTE has been well validated (1). However, research into VTE predictability models is inadequate (2) , especially in the aftermath of acute stroke, when development of clot in leg veins can be as early as 48 hours and early in the second week (3, 4) . The impact of improved and organised specialist stroke intervention, including thrombolytic therapy on clinical outcome is well known (5) (6) (7) . However, the effects of this specialist input, thrombolytic therapy in ischaemic stroke, and thromboprophylaxis on incidence of VTE in the era of hyperacute stroke care is yet unknown. In previous studies, the incidence of symptomatic VTE is 1-20% (8, 9) , with subclinical incidence of 8-75% (10) (11) (12) . There remains lack of clarity in International guidelines on timing of thromboprophylaxis (13) (14) (15) (16) . Thus a VTE prediction model to identify those at high risk who will benefit from early thromboprophylaxis is desirable. We postulate that in the aftermath of acute stroke, and independent of the clinical intervention approach to the overall stroke care, markers of haemostatic activation due to endothelial perturbation and/or stroke severity may predict those at risk of developing DVT. We investigate the role of laboratory factors (thrombin generation, D-dimer, fibrinogen) alongside clinical factors (National Institute of Health Stroke Scale and Barthel Index) M A N U S C R I P T ACCEPTED MANUSCRIPT 2 in improving pretest probability. NIHSS is a measure of stroke severity and Barthel index is a measure of functional abilities. Thrombin generation is a novel global coagulation assay which has been used in non stroke patients as a research tool to risk stratify for recurrent VTE (17, 18) , and in the diagnosis of first DVT (19) (20) (21) .
Methods

Study objectives
1. To predict DVT after acute stroke using markers of haemostatic activation and stroke severity scores.
2. To define incidence of DVT in the era of hyperacute stroke care. and August 2011. Participants with an objective diagnosis of stroke were invited to take part within 48 hours of admission. Patients with radiological diagnosis of stroke after 48 hours or those on end of life care within 48 hours of admission and life expectancy less than 7 days were excluded. Other reasons for exclusion were early repatriation to local hospitals, refusal to continue with study after screening, previous DVT/PE, previous diagnosis of cancer, prior anticoagulant therapy, and previous lower limb amputation. All participants had baseline NIHSS, BI recorded. The height (m) and weight (kg) of all participants were measured to allow calculation of body mass index (BMI). Past medical history, including past cardiovascular, cerebrovascular history, and medication history were recorded. All patients were screened for DVT in week 2 using compression Doppler ultrasound scan, as described below. If there was clinical suspicion of PE participants were investigated with CT pulmonary angiogram. All patients with diagnosis of ischaemic stroke received Aspirin 75mg once daily and Dipyridamole MR 200mg twice daily within 24 hours of admission. And considering there was no concensus on routine thromboprophylaxis.
This was commenced after compression ultrasound scan in week 2 if no DVT was found. Otherwise patients with objective evidence of DVT were treated with bridging therapy of clexane and warfarin. Platelet poor plasma (PPP) for thrombin generation was prepared by centrifugation of blood sample in the sodium citrate plastic vacutainer using Hettich Rotina 420R centrifuge (Hettich, Tuttlingen, Germany) at 4750g for 10 minutes, at room temperature. After the initial centrifugation, the top three-quarters of supernatant was decanted into a polypropylene tube and then centrifuged a second time at 4750g for 10 minutes again at room temperature. The top three-quarter of the supernatant was transferred into a plastic tube, and stored at -40 o C. Samples were processed and frozen within 60 minutes of collection.
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
Plasma for D-dimer and Clauss fibrinogen was prepared by single centrifugation at 3040g for 7 minutes and tested within 4 hours.
Thrombin generation was undertaken within 12 weeks of sample collection, following further centrifugation after plasma thawing at 4750g for 10 minutes. Intra-assay and inter-assay variability was < 5% and <12% respectively for all thrombin generation parameters.
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Laboratory assays
Thrombin generation
Thrombin generation was measured in platelet poor plasma (PPP) with the Thrombinoscope TM assay (Thrombinoscope BV, Maastrichts, Netherlands) as previously described (22, 23) . Final tissue factor concentration was 5pM with 4µM of phospholipids. Parameters measured were lag time (minutes), time to peak (ttP, minutes), peak thrombin generation (nM) and endogenous thrombin potential (ETP), which is the area under the curve (nM.min).
Standard coagulation assay D-dimer was measured by a latex photometric immuno-assay and Clauss fibrinogen using Diagnostica Stago reagents (Asnieres, France) on the automated STA® Evolution analyser(Diagnostica Stago) as described previously (24) .
Duplex compression ultrasound scan
All participants had bilateral whole leg duplex compression ultrasound scan 
Results
Participant demographics and risk factors
Five hundred participants were screened, with exclusions as shown in the Study algorithm in figure 1.
188 participants gave consent and were recruited into the study. From this number, 96 participants withdrew due to early repatriation to local hospitals, medical complications such as severe septicaemia, bleeding diastheses, renal failure requiring frequent dialysis, upper gastrointestinal bleeding requiring intensive therapy unit admissions, New York Heart Association class IV heart failure and acute severe myocardial infarction. These participants were moribund and were as a result unfit for further investigations including Doppler ultrasound scan. The remaining participants (n=92) had complete investigations. Of these numbers, there were 9
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Relationship between thrombin generation and DVT
Relationship between D-dimer, fibrinogen and DVT
At both baseline, and week 2, patients with DVT had significantly higher D-dimer levels, as shown in Table 2 . In the DVT group median D-dimer was significantly higher at baseline (2280ng/mL Vs 1035ng/mL, p=0.001) and in the second week (2240 ng/mL Vs 970 ng/mL; p<0.001).
A graphical illustration of the difference in D-dimer values between the two groups is shown in. Box plot in figure 2a showed the association between baseline D-dimer (time 1) and DVT, while box plot in figure 2b , showed the association between week 2, (time 2) D-dimer and DVT. There were no difference in fibrinogen levels between the two groups.
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Discussion
In this study, the incidence of DVT remained high (19.6%) despite specialist care input and a significant proportion of patients receiving thrombolytic therapy. This contrasts with clinical experience on the association between good practices regarding specialist stroke care reduce incidence of DVT. Amongst participants receiving thrombolytic therapy, 21% had DVT and this constitute 40% of DVT in the ischaemic stroke group. The incidence of DVT in our patient population may be partially attributable to the existing guidelines in the United Kingdom, which do not support the use of pharmacological prophylaxis in acute stroke patients and theoretical risks of haemorrhagic transformation of infarct and probable extension of an intracerebral haematoma. Secondly, this incidence can also partly be explained by development of DVT prior to demonstration of neurological recovery and early mobilisation, considering most patients were mobilised 24 hours after thrombolytic therapy.
Immobility due to motor limb weakness is a major risk factor for VTE (25) (26) (27) , and development of thrombus in deep veins may have commenced as early as 48 hours following stroke (3, 4) . In support of this we confirmed that DVT was associated with measures of impairment and disability after acute stroke. More patients with DVT had significant motor limb weakness, significant functional inability, with lower
Barthel index, and greater stroke severity score with higher NIHSS. Thirdly, lack of protection against DVT in patients offered thrombolyic therapy may be due to short half life of r-tPA, it also suggest that early DVT prophylaxis in addition to the overall hyperacute stroke care is required. In previous studies, raised serum urea which can be a marker of dehydration, and other acute inflammatory markers, such as fibrinogen and CRP were associated with DVT (28) (29) (30) (31) . We did not demonstrate an association between DVT and fibrinogen.
Our study is the first to examine thrombin generation in the aftermath of acute stroke, and to demonstrate that D-dimer has potential clinical utility in suggesting at risk patients after acute stroke. We theorised that an increase in thrombin generation may indicate a predisposition to thrombus formation in the aftermath of acute stroke (32, 33) , and therefore predict those patients that will eventually develop DVT. However, no association was found between thrombin generation and DVT. The lack of a link with thrombin generation, suggests that factors other than a generalised prothrombotic tendency determines the development of DVT after acute stroke. We
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13 confirmed previous findings, that 2-point D-dimer values were significantly associated with DVT. D-dimer assay around day 9 has been shown to have good discriminatory power for predicting proximal DVT after acute ischaemic stroke (34).
Harvey et al in a similar study (n=105) showed D-dimer assay within 24 hours of stroke, at cut point of 1591 ng/mL, gives 79% sensitivity, 78% specificity, 35%
positive predictive value, and 96% negative predictive value (27) . We found D-dimer assay within 48 hours of stroke at a cut-off of 1660 ng/mL had similar clinical utility in suggesting underlying DVT burden. At this cut point, 13/18 (72%) with asymptomatic DVT were identified. Baseline D-dimer is as effective as D-dimer measured at later time points in suggesting underlying risk of DVT, and as a result early elevation in D-dimers might be useful in risk stratifying patients need for thromboprophylaxis. D-dimer assay is a readily available, automated, and cheap test, in comparison to thrombin generation assay, and could therefore be easily integrated into a pretest assessment model even within the stroke population. Early initiation of pharmacological prophylaxis (within 48 hours) in studies of stroke patients showed significant reduction in VTE and with a non significant increased risk of intracerebral haemorrhage after acute ischaemic stroke (35, 36) . Most international guidelines recommend pharmacological prophylaxis in immobile and high risk patients, but there is no clarity on the time of initiation (14) (15) (16) 36) . Inclusion of D-dimer in future risk stratification criteria may assist in identifying those that will benefit from early detection. Early detection may further assist in making decisions on prompt initiation of thromboprophylaxis, and possibly limit the number needed to treat, and thereby reducing the overall risk of bleeding. Low Barthel index at a cut-off of ≤ 6 should raise clinical suspicion, but not as an independent factor to predict DVT risk as previously shown in a study were association with proximal DVT was found at a higher cut-off of ≤ 9 (37). Ogata et al, previously demonstrated an association between DVT and high NIHSS after acute haemorrhagic stroke (11) and at a threshold of ≥ 14, pharmacological prophylaxis was found to be safe and effective (36) . At NIHSS of ≥ 14, 67% of DVT could have been predicted (67% sensitivity)
but not as an independent factor. D-dimer remained the only independent factor with good clinical utility to predict DVT.
Limitations of this study relate to the population investigated, with 48.9% of those enrolled completing the follow up, this may not have altered the results on incidence A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 14 considering that those discharge early were ambulatory within 48 hours and are the groups less likely to have developed DVT and were more likely to return for follow up. Due to geographical location of the study centre as a regional hyperacute stroke referral centre, early repatriation was unavoidable, and follow up of participants with severe stroke in local hospitals was impractical due to differences in local hospital specialist input practices and differences in DVT imaging techniques. Adjustment was made for the expected missing data in our analysis. Application of our findings in participants with short hospital stay has limitations. Given the short duration of follow up, and that the risk of DVT remains up to 3 months (38, 39) , it is possible a number of later DVT events were missed. Lastly, due to heterogenous patient population and small sample size, we are unable to undertake subgroup analysis in relation to stroke subtypes and those that received thrombolytic therapy.
In conclusion, we have demonstrated that DVT remains a common complication after acute stroke, despite thrombolytic therapy and improved specialist stroke care input, suggesting a need for additional thromboprophylaxis. In our study population Ddimer assay was independently associated with DVT, thus suggesting underlying DVT risk, when compared to other coagulation assays and measures of stroke severity. Further research to establish the role of D-dimer in identifying acute stroke patients at risk of DVT for early thromboprophylaxis is desirable.
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